Boxer Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0002018299

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q2 2026 · 63 positions · Total reported value $1.33B · Top-10 concentration 65.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 24.2% · 12 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +34.8% · vs SPY +19.9% · Prev Value $761.65M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Boxer Capital Management, LLC disclosed 63 equity positions with a combined reported value of $1.33B. The filing implies a focused portfolio: its ten largest positions account for 65.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were TNGX ($339.99M), RVMD ($93.64M), ABVX ($80.62M). By sector, the heaviest allocations are Health Care 98.5%, Other 1.5%. Versus the prior quarter, allocation shifted toward Health Care (+2.8pp) and away from Other (-2.8pp).

Versus the prior quarter, Boxer Capital Management, LLC opened 12 new positions, trimmed 1 and fully exited 3, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q2 2026 were QTTB ($40.12M), SYRE ($8.88M), RLAY ($8.42M).

Of the 3 positions fully exited versus the prior quarter, the largest were TERN ($19.77M), SLNO ($6.70M), KALV ($410.65K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • QTTB Q32 BIO INC · $40.12M
  • SYRE SPYRE THERAPEUTICS INC · $8.88M
  • RLAY RELAY THERAPEUTICS INC · $8.42M
  • KZIA KAZIA THERAPEUTICS LTD · $7.88M
  • STTK SHATTUCK LABS INC · $6.94M
  • FBRX FORTE BIOSCIENCES INC · $5.83M
  • ODTX ODYSSEY THERAPEUTICS INC · $5.15M
  • IMTX IMMATICS N.V · $4.81M

Fully Exited (vs previous quarter)

  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $19.77M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $6.70M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $410.65K

Insider Transactions (Form 4)

Latest Boxer Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Boxer Capital Management, LLC is an SEC-registered 13F filer based in San Diego, CA, United States. As of Q2 2026 it reported 63 US equity positions with a combined value of $1.33B. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Firm Snapshot

  • Headquarters: SAN DIEGO, CA, United States
  • SEC registration: 801-130351 (status: Approved), registered 2024-05-24
  • Regulatory AUM (Form ADV): $578.22M as of 2026-05-11
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds
  • Website: boxercap.com

Portfolio Structure

  • 63 positions · $1.33B reported value (Q2 2026)
  • Top 10 holdings = 65.1% of reported value
  • Largest position: TNGX (TANGO THERAPEUTICS INC COM) at 25.6%
  • Average position size: $21.08M

Sector Tilt

  • Health Care 98.5%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 12 new, 17 added, 1 reduced, 3 exited
  • 33 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Boxer Capital Management's 2026-Q2 rebalancing indicates a cautious approach with a focus on healthcare, possibly reflecting a belief in the long-term potential of the sector or specific biotech trends. 2. Key Moves: - Added: ABVX, QURE, KOD, KYMR, DFTX, REPL, CELC, QTTB. The additions are significant, with ABVX and QURE showing substantial increases in share count. - Reduced: None noted in the provided information. - Hold: TNGX, RVMD. Both holdings were maintained with no changes in share count or action. 3. Portfolio Structure: - Passive/Active: The fund appears to be actively managed, as evidenced by the significant additions and changes in share count for several holdings. - Sector Bias: Strong bias towards the healthcare sector, particularly biotechnology and pharmaceuticals. - Risk Appetite: The addition of high-growth potential biotech companies suggests a moderate to high risk appetite, as these stocks are often more volatile. 4. Per-Holding One-Liner: - TNGX: TANGO THERAPEUTICS INC - Developing therapies for rare genetic disorders. - RVMD: REVOLUTION MEDICINES INC - Focused on novel cancer immunotherapies. - ABVX: ABIVAX SA - Developing treatments for infectious diseases. - QURE: UNIQURE NV - Specializes in gene therapy for various genetic disorders. - KOD: KODIAK SCIENCES INC - Developing treatments for rare genetic diseases. - KYMR: KYMERA THERAPEUTICS INC - Focused on novel therapies for cancer and inflammatory diseases. - DFTX: DEFINIUM THERAPEUTICS INC COM - Engaged in the development of treatments for cancer and other diseases. - REPL: REPLIMUNE GROUP INC - Developing immunotherapies for cancer. - CELC: CELCUITY INC - Specializes in cancer immunotherapy. - QTTB: Q32 Bio Inc. - Developing therapies for rare genetic diseases. - Unverified: None provided in the information. 5. One-Sentence Style Summary: Boxer Capital Management's 2026-Q2 rebalancing reflects a strategic move into high-growth biotech companies, signaling a focus on the healthcare sector's potential for innovation and significant returns.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 98.5%
Other 1.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 10.88M $339.99M 25.61%
25.61%
Hold
2 500.00K $93.64M 7.05%
7.05%
Hold
3 605.00K $80.62M 6.07%
6.07%
Add
4 1.50M $69.24M 5.21%
5.21%
Add
5 1.48M $57.57M 4.34%
4.34%
Add
6 429.10K $49.20M 3.71%
3.71%
Add
7 998.50K $46.97M 3.54%
3.54%
Add
8 3.98M $44.09M 3.32%
3.32%
Add
9 416.53K $43.58M 3.28%
3.28%
Add
10 3.15M $40.12M 3.02%
3.02%
New
11 1.40M $33.60M 2.53%
2.53%
Add
12 5.15M $29.36M 2.21%
2.21%
Add
13 335.50K $29.17M 2.20%
2.20%
Add
14 1.11M $26.96M 2.03%
2.03%
Add
15 170.00K $20.84M 1.57%
1.57%
Hold
16 1.87M $19.01M 1.43%
1.43%
Hold
17 325.00K $18.89M 1.42%
1.42%
Hold
18 500.00K $18.40M 1.39%
1.39%
Hold
19 1.10M $16.43M 1.24%
1.24%
Hold
20 200.00K $16.31M 1.23%
1.23%
Hold
21 46.46K $15.55M 1.17%
1.17%
Hold
22 800.00K $14.37M 1.08%
1.08%
Hold
23 1.30M $12.77M 0.96%
0.96%
Add
24 2.81M $11.57M 0.87%
0.87%
Add
25 4.80M $10.03M 0.76%
0.76%
Hold
26 70.00K $9.29M 0.70%
0.70%
Hold
27 100.00K $8.88M 0.67%
0.67%
New
28 225.00K $8.71M 0.66%
0.66%
Hold
29 100.00K $8.52M 0.64%
0.64%
Hold
30 450.00K $8.42M 0.63%
0.63%
New
31 453.69K $8.17M 0.61%
0.61%
Hold
32 494.00K $8.10M 0.61%
0.61%
Hold
33 560.00K $7.88M 0.59%
0.59%
New
34 1.00M $6.94M 0.52%
0.52%
New
35 375.00K $6.93M 0.52%
0.52%
Add
36 274.50K $5.83M 0.44%
0.44%
New
37 842.11K $5.83M 0.44%
0.44%
Hold
38 275.00K $5.35M 0.40%
0.40%
Hold
39 900.00K $5.31M 0.40%
0.40%
Hold
40 790.00K $5.22M 0.39%
0.39%
Add
41 275.00K $5.15M 0.39%
0.39%
New
42 475.00K $4.81M 0.36%
0.36%
New
43 180.50K $4.51M 0.34%
0.34%
New
44 75.00K $4.03M 0.30%
0.30%
Hold
45 350.00K $3.79M 0.28%
0.28%
Add
46 749.03K $3.63M 0.27%
0.27%
Hold
47 2.00M $3.40M 0.26%
0.26%
New
48 2.84M $3.13M 0.24%
0.24%
Add
49 1.50M $3.12M 0.23%
0.23%
Reduce
50 300.00K $3.00M 0.23%
0.23%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 42% of its Top-10 each quarter and backtests at F1 60% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (5 quarters)

Avg precision 60% · recall 60% · F1 60% · avg rank error 2.9 · Top-10 turnover 42%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 40% 40% 40% RVMD · NUVL · MRUS · ANAB · RNAM · XENE · REPL · CMRX · TNGX · APLS TNGX · RVMD · REPL · MRUS · KYMR · QURE · ITOS · URGN · AMLX · CBIO
2025-Q3 70% 70% 70% TNGX · RVMD · REPL · KYMR · MRUS · QURE · ITOS · URGN · AMLX · CBIO TNGX · QURE · RVMD · KYMR · KOD · PTCT · AMLX · URGN · MRUS · CYTK
2025-Q4 60% 60% 60% TNGX · QURE · KYMR · RVMD · PTCT · KOD · URGN · AMLX · CYTK · ABVX TNGX · RVMD · KOD · KYMR · CELC · ABVX · PTCT · TERN · PTGX · PRAX
2026-Q1 70% 70% 70% TNGX · KOD · RVMD · CELC · KYMR · ABVX · PTGX · PTCT · PRAX · TERN TNGX · KOD · RVMD · KYMR · CELC · SRZN · ABVX · TERN · PCVX · CAPR
2026-Q2 ★ 60% 60% 60% TNGX · KOD · RVMD · CELC · KYMR · SRZN · ABVX · CAPR · PTGX · VIR TNGX · RVMD · ABVX · QURE · KOD · KYMR · DFTX · REPL · CELC · QTTB

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Boxer Capital Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Boxer Capital Management, LLC reported 63 equity positions worth $1.33B in aggregate; its largest disclosed positions were TNGX ($339.99M), RVMD ($93.64M), ABVX ($80.62M).

How large is Boxer Capital Management, LLC's portfolio?

Boxer Capital Management, LLC reported $1.33B of long equity holdings across 63 positions as of 2026-Q2. Top-10 holdings account for 65.1% of reported value.

What is Boxer Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/boxer-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →